Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]

touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]

We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]

Ahead of International NASH Day, we had the pleasure of meeting with the Global Liver Institute Founder, President and Chief Executive Officer Donna Cryer to discuss this year’s theme ‘Stop NASH Now’, and the importance of endocrinologists in the NASH patient journey. Questions How does GLI help support patients and their endocrinologists? (0:28) This year’s […]

touchENDOCRINOLOGY caught up with Prof Lise Lotte Gluud (Copenhagen University Hospital, Hvidovre, Denmark) virtually during the EASD Annual Meeting 2021 conference to discuss her study on the effect of subcutaneous semaglutide on features of the metabolic syndrome in patients with non-alcoholic steatohepatitis. Questions 1. Could you give us a brief overview of the association of […]

touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Are you pleased with how the European Association for the Study of the Liver (EASL) NAFLD Summit 2021 went this year? (00:23-01:00) 2. What were […]

touchENDOCRINOLOGY joins Prof. Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (0:20) 2. What are the current most […]

It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]

TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]